225 related articles for article (PubMed ID: 38265550)
1. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages.
Park R; Yu J; Shahzad M; Lee S; Ji JD
Immunol Res; 2024 Jan; ():. PubMed ID: 38265550
[TBL] [Abstract][Full Text] [Related]
2. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
[TBL] [Abstract][Full Text] [Related]
4. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma.
Mao Y; Chen L; Wang F; Zhu D; Ge X; Hua D; Sun J
Oncol Lett; 2017 Nov; 14(5):6177-6183. PubMed ID: 29113264
[TBL] [Abstract][Full Text] [Related]
6. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
8. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T
Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560
[TBL] [Abstract][Full Text] [Related]
9. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
10. Correction to: The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages.
Park R; Yu J; Shahzad M; Lee S; Ji JD
Immunol Res; 2024 Feb; ():. PubMed ID: 38383812
[No Abstract] [Full Text] [Related]
11. Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.
Trieu V; Maida AE; Qazi S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539537
[TBL] [Abstract][Full Text] [Related]
12. A promising target for breast cancer: B7-H3.
Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
[TBL] [Abstract][Full Text] [Related]
13. High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis.
Zhang D; Huang H; Gao X; Yu G; Zhang X; Jin H; Xu R; Wang Z; Zhang G
Transl Oncol; 2024 Mar; 41():101874. PubMed ID: 38262113
[TBL] [Abstract][Full Text] [Related]
14. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting PP2A Upregulates B7-H3 Expression and Potentially Increases the Sensitivity of Malignant Meningiomas to Immunotherapy by Proteomics.
Hu B; Hao S; Miao Y; Deng Y; Wang J; Wan H; Zhang S; Ji N; Feng J
Pathol Oncol Res; 2022; 28():1610572. PubMed ID: 36203966
[TBL] [Abstract][Full Text] [Related]
18. Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis.
Purvis IJ; Avilala J; Guda MR; Venkataraman S; Vibhakar R; Tsung AJ; Velpula KK; Asuthkar S
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382461
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression.
Kang FB; Wang L; Li D; Zhang YG; Sun DX
Oncol Rep; 2015 Jan; 33(1):274-82. PubMed ID: 25370943
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 role in the immune landscape of cancer.
Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
